Lixisenatide Acetate
Supplier: BACHEM AMERICAS INC
Lixisenatide is an exenatide-related GLP-1 agonist injected once daily for glycemic control in adult diabetes II. In myocardial ischemia-reperfusion injury studies with rats, a cardioprotective activity could be shown. Furthermore, administration of lixisenatide rescued spatial memory and synaptic plasticity from amyloid β-protein-induced impairments. Offered under Bolar Exemption: All APIs that are sold for development of drug products still patent protected are offered under Bolar Exemption only. The following disclaimer applies: These products are offered and sold in small quantities only and solely for uses reasonably related to privileged trials and studies for obtaining marketing authorization required by law (Bolar Exemption). Bachem cannot be made liable for any infringement of intellectual property rights. It is the sole and only responsibility of the purchaser or user of these products to comply with the relevant national rules and regulations.
Learn more

About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...